Artelo Biosciences terminated its at-the-market offering agreement with R.F. Lafferty, effective May 18, 2026, after selling 50,858 shares for $451,527 in gross proceeds.
Key takeaways
Termination of ATM agreement with R.F. Lafferty effective May 18, 2026.
Company sold 50,858 shares for $451,527 gross proceeds under the agreement.
Agreement allowed up to $6.5 million in common stock sales.
No further equity sales through this facility after termination.